Back

Dual AAV amelioration of Lama2-null muscular dystrophy and neuropathy

McKee, K. K.; Yurchenco, P. D.

2026-02-10 pathology
10.64898/2026.02.09.704845 bioRxiv
Show abstract

The dy3K/dy3K Lama2-/- mouse is a model for the severe form of LAMA2-related dystrophy and peripheral neuropathy (LAMA2-RD). In the dystrophic mice, a compensating laminin subunit, Lm4, that lacks polymerization and -dystroglycan-binding activity, replaces the missing Lm2 subunit. It was previously found that an 4-laminin can be modified with two small laminin-binding linker proteins, i.e. LNNd{Delta}G2 and miniagrin to facilitate polymerization and -dystroglycan binding respectively, to enable the key missing functions. Adeno-associated virus serotype 9 (AAV9) was used to deliver minigenes coding for the two proteins in dystrophic mice. AAV9-LNNd{Delta}G2 utilized a universal CBh promoter while AAV9-miniagrin utilized either the CBh promoter or muscle-specific SPc5-12 promoter. The phenotype in the dy3K/dy3K mice was evaluated following i.v. postnatal injection with either AAV9 -LNNd{Delta}G2 alone or in combination with AAV9- LNNd{Delta}G2 + AAV9- miniagrin. Double AAV treatment was found to substantially increase survival and ambulation, as well as increase forelimb grip-strength and improve muscle histology. Of note, the sciatic nerve amyelination characteristic of laminin 2-deficiency was prevented. While single treatment with LNNd{Delta}G2 was inferior to double treatment for muscle strength and survival, it corrected the radial sorting deficit equally, revealing that enablement of laminin polymerization is a sufficient requirement for myelination. HighlightsO_LIThe dy3K/dy3K (Lama2-/-) mouse, a model for severe LAMA2-related dystrophy, expresses laminin-411 that is unable to polymerize or bind to -dystroglycan (DG). C_LIO_LILNNd{Delta}G2 and miniagrin are laminin-411-binding proteins that enable polymerization and DG binding. C_LIO_LIAAV9 delivery of genes coding for LNNd{Delta}G2 and miniagrin ameliorated the dystrophic phenotype in muscle and nerve (survival, growth, mobility, and grip-strength, muscle and nerve histopathology). C_LIO_LISciatic nerve amyelination was prevented by LNNd{Delta}G2 alone. C_LI

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Molecular Therapy
71 papers in training set
Top 0.1%
14.8%
2
Disease Models & Mechanisms
119 papers in training set
Top 0.1%
10.2%
3
JCI Insight
241 papers in training set
Top 0.5%
6.4%
4
Human Molecular Genetics
130 papers in training set
Top 0.3%
6.4%
5
The American Journal of Pathology
31 papers in training set
Top 0.1%
6.4%
6
Journal of Clinical Investigation
164 papers in training set
Top 0.5%
4.9%
7
EMBO Molecular Medicine
85 papers in training set
Top 0.4%
4.0%
50% of probability mass above
8
Nature Communications
4913 papers in training set
Top 39%
3.6%
9
Brain
154 papers in training set
Top 2%
3.1%
10
Neurobiology of Disease
134 papers in training set
Top 2%
1.9%
11
Experimental Neurology
57 papers in training set
Top 0.5%
1.8%
12
Science Translational Medicine
111 papers in training set
Top 2%
1.7%
13
eLife
5422 papers in training set
Top 41%
1.7%
14
Cell Reports Medicine
140 papers in training set
Top 4%
1.7%
15
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.2%
1.7%
16
Skeletal Muscle
14 papers in training set
Top 0.1%
1.5%
17
Scientific Reports
3102 papers in training set
Top 66%
1.2%
18
Muscle & Nerve
10 papers in training set
Top 0.3%
1.1%
19
The Journal of Pathology
22 papers in training set
Top 0.3%
1.1%
20
Acta Neuropathologica Communications
81 papers in training set
Top 0.8%
1.1%
21
Stem Cell Reports
118 papers in training set
Top 0.8%
0.9%
22
Molecular Therapy - Nucleic Acids
24 papers in training set
Top 0.3%
0.8%
23
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.8%
0.8%
24
Stem Cell Research & Therapy
30 papers in training set
Top 0.8%
0.8%
25
iScience
1063 papers in training set
Top 34%
0.7%
26
PLOS ONE
4510 papers in training set
Top 69%
0.7%
27
Cell Death & Disease
126 papers in training set
Top 3%
0.7%
28
Science Advances
1098 papers in training set
Top 33%
0.6%
29
PNAS Nexus
147 papers in training set
Top 3%
0.6%
30
The Lancet
16 papers in training set
Top 0.9%
0.6%